Trial Profile
12 month, multi-center, open-label, prospective, randomized, parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican based regimen either in combination with Cyclosporin A or Tacrolimus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate mofetil; Mycophenolate sodium; Tacrolimus
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Acronyms ATHENA
- Sponsors Novartis Pharma
- 01 Sep 2021 Interim results presented at the 20th Congress of the European Society for Organ Transplantation
- 01 Sep 2021 Results of post-hoc analysis presented at the 20th Congress of the European Society for Organ Transplantation
- 09 Jun 2021 Results of post-hoc analysis presented at the 2021 American Transplant Congress.